Company Profile
Lixte Biotechnology Holdings Stock Price, News & Catalysts
- Ticker:
- LIXT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.21 USD (-6.00%)
Close
Last updated: July 2, 2026
87.2M USD
Market cap
Why the stock is moving
The latest monitored company update is “NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE.” Closing-price data for the corresponding market session is incomplete, so a relative move was not calculated.
Company overview
PP2A Inhibition in Cancer
LIXTE Biotechnology develops cancer therapies based on inhibition of protein phosphatase 2A. Its lead molecule is intended to sensitize tumors to chemotherapy and immunotherapy rather than function solely as a stand-alone cytotoxic drug.
LB-100
LB-100 is a first-in-class clinical PP2A inhibitor that has shown tolerability at biologically active doses. Proof-of-concept studies are evaluating combinations in ovarian clear-cell carcinoma, metastatic colorectal cancer and advanced soft-tissue sarcoma.
Proton-Therapy Technology
Through Liora Technologies Europe, LIXTE is also developing the LiGHT System, an electronically controlled proton-therapy platform. This med-tech program broadens the company beyond drug development into precision radiation treatment.
Future catalysts
- Lixte’s catalysts are oncology pipeline updates and any strategic move that clarifies the company’s next step. The market will care about whether there is still a viable clinical path.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lixte Biotechnology Holdings (LIXT)?
Lixte Biotechnology Holdings (LIXT) most recently closed at 7.21 USD, a -6.00% move versus the previous session.
What is the market cap of Lixte Biotechnology Holdings (LIXT)?
Lixte Biotechnology Holdings currently has a market capitalization of 87.2M USD on BioPharmSignal.
What does Lixte Biotechnology Holdings do?
PP2A Inhibition in Cancer LIXTE Biotechnology develops cancer therapies based on inhibition of protein phosphatase 2A. Its lead molecule is intended to sensitize tumors to chemotherapy and immunotherapy rather than function solely as a stand-alone cytotoxic drug. LB-100 LB-100 is a first-in-class clinical PP2A inhibitor that has shown tolerability at...
On which exchange is LIXT stock listed?
Lixte Biotechnology Holdings (LIXT) is associated with NASDAQ, United States, Biopharma.
What is LB-100?
LB-100 LB-100 is a first-in-class clinical PP2A inhibitor that has shown tolerability at biologically active doses.
Which conditions is Lixte Biotechnology Holdings targeting with LB-100?
Lixte Biotechnology Holdings is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Lixte Biotechnology Holdings describe recent progress with LB-100?
Lixte’s catalysts are oncology pipeline updates and any strategic move that clarifies the company’s next step. The market will care about whether there is still a viable clinical path.
What is of-concept?
Proof-of-concept studies are evaluating combinations in ovarian clear-cell carcinoma, metastatic colorectal cancer and advanced soft-tissue sarcoma.